Lupin

Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in Cardiovasculars, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.

Christoph Funke

President and Chief Technical Operations Officer

Abdelaziz Toumi

CEO

9 past transactions

Southern Cross Pharma

Acquisition in 2021
Southern Cross Pharma is a privately owned pharmaceutical company that operates in the Australian and New Zealand markets. The company specializes in the development, registration, and distribution of generic pharmaceutical products. Its primary focus is on supplying prescription medications to retail pharmacies while also directly marketing its own-brand products, known as SXP, to hospitals. This dual approach allows Southern Cross Pharma to efficiently meet the demands of its clients, ensuring a reliable supply of medications to end consumers.

Symbiomix Therapeutics

Acquisition in 2017
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.

Temmler Werke

Acquisition in 2015
The Temmler Group, with its 7 production sites in Europe, is one of the largest providers of contract services in the pharmaceutical environment. Temmler has a wide experience in formulation development of finished solid, semi-solid and liquid dosage forms, in manufacture, packaging, blinding, distribution and return handling of clinical trial supplies, in the optimization of established manufacturing processes as well as in the contract manufacture of medicinal products with marketing authorization, supplemented by Quality Control and Analytical services. Temmler offers services from stand-alone processes according to customer specifications, to strategic services comprising the entire supply chain.

Gavis Pharmaceuticals

Acquisition in 2015
GAVIS Pharmaceuticals, LLC is a niche drug product sales and distribution company.

Novel Laboratories

Acquisition in 2015
Novel Laboratories, Inc., a pharmaceutical company, engages in the research, development, and manufacture of generic and branded products in a range of therapeutic classes and dosage forms. Its product portfolio comprises immediate and modified release tablets; capsules and powders; liquids, such as solutions and suspensions; topical products, including gels, lotions, foams, ointments, and creams; respiratory products; vaginal and rectal suppositories; otic products, including solutions and suspensions; injectables, such as lyophilized powder and solutions in vials, ampules, and large volume parenterals; and ophthalmic solutions and suspensions droppers.

JSC Biocom

Acquisition in 2015
JSC Biocom is a pharmaceutical manufacturer based in Stavropol, Russian Federation, established in 1991. The company specializes in the production of generic products, available in tablet and capsule forms. Its product range includes agents that target various systems such as the hemopoietic, cardiovascular, alimentary, nervous, and musculoskeletal systems, in addition to dermatological and antimicrobial agents. JSC Biocom also provides pharmaceutical contract manufacturing services, contributing to its role in the broader healthcare market. As of July 31, 2015, it operates as a subsidiary of Lupin Limited.
Medquímica Indústria Farmacêutica S.A. is a Brazilian pharmaceutical company established in 1975 and headquartered in Juiz de Fora, Brazil. The company specializes in the development of solid and liquid medications, offering a range of products that includes over-the-counter drugs, generics, hospital medications, dietary supplements, and herbal products. It serves customers through a network of representatives across Brazil. As of 2015, Medquímica operates as a subsidiary of Lupin Limited.

Pharma Dynamics

Acquisition in 2015
Pharma Dynamics (Pty) Ltd. is a pharmaceutical company based in Cape Town, South Africa, founded in 2001. The company specializes in providing a wide range of generic pharmaceuticals and offers products across various therapeutic categories, including cardiovascular, central nervous system, and pediatric care. Additionally, Pharma Dynamics supplies over-the-counter medications for conditions such as cold and flu, allergies, heartburn, and immune support. The company also focuses on critical hospital products, which include antibiotics and specialty healthcare solutions for both male and female patients. Pharma Dynamics primarily serves the South African market and operates as a subsidiary of Lupin Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.